Self-Assessment: Immune Mediated Peripheral Neuropathies | Paradigm Clashes: Debate & Exploration in Choosing Traditional vs Novel Immunotherapeutics for MG-Immune Mediated Peripheral Neuropathies: Dr. Vazquez Do Campo Presentation

Immune Mediated Peripheral Neuropathies: Dr. Vazquez Do Campo Presentation

Pdf Summary

The document focuses on Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and its variants, presented by Dr. Rocio Vazquez Do Campo. CIDP is a spectrum of immune-mediated demyelinating neuropathies, often diagnosed with unclear risk factors and lacking specific biomarkers. Prevalence is 1-9 per 100,000, mostly affecting males in their 40s to 60s. CIDP diagnosis is complicated due to overlapping symptoms with other neuropathies, leading to an issue of both overdiagnosis and underdiagnosis.<br /><br />There are typical and variant forms of CIDP. Typical CIDP is the most common, characterized by symmetric weakness and sensory loss in limbs, with diagnoses requiring EDX confirmation of demyelination in motor and sensory nerves. Variants include distal, multifocal, focal, motor, and sensory CIDP, each with distinct clinical presentations and diagnostic challenges. For instance, distal CIDP involves sensory loss in lower and upper limbs, often linked to anti-MAG antibodies, while multifocal CIDP presents as asymmetric limb involvement.<br /><br />Autoimmune nodopathies, characterized by immune attacks at the nodes of Ranvier, are differentiated by their unique antibody targets and require distinct treatment approaches. These include testing for antibodies like contactin-1 and neurofascin-155 in cases with atypical presentations such as resistance to standard treatments and associated severe symptoms.<br /><br />The document emphasizes the importance of differentiating CIDP from similar neuropathies, such as anti-MAG neuropathy, Multifocal Motor Neuropathy (MMN), and Chronic Immune Sensory Polyradiculopathy (CISP), for appropriate management. Important takeaways include the use of monoclonal protein screening and nodal/paranodal antibody testing in atypical CIDP cases. <br /><br />Overall, the presentation underscores the complexity of diagnosing CIDP and its variants, advocating for careful differentiation from other neuropathies and the need for precise treatment strategies.

Keywords

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

CIDP

Chronic Inflammatory Demyelinating Polyneuropathy

demyelinating neuropathies

diagnostic challenges

autoimmune nodopathies

antibody testing

multifocal CIDP

anti-MAG antibodies

neuropathy differentiation

treatment strategies

cidp

Chronic Inflammatory Demyelinating Polyneuropathy